Vanda Pharmaceuticals and the FDA have agreed to lay down their swords, squashing years of legal disputes with an agreement that will see regulatory action on much of Vanda’s grievances. The ...
The FDA’s rejection of Vanda Pharmaceuticals’ stomach disease candidate has done little to dampen the enthusiasm of England’s Cycle Pharmaceuticals to acquire the Washington D.C.-based company. On ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results